|
gptkbp:instance_of
|
gptkb:monoclonal_antibody
|
|
gptkbp:activities
|
inhibits IL-23 pathway
|
|
gptkbp:clinical_trial
|
Phase III
chronic inflammatory skin disease
C-016
C-017
C-018
|
|
gptkbp:contraindication
|
active infections
hypersensitivity to tildrakizumab
|
|
gptkbp:developed_by
|
gptkb:Merck_&_Co.
|
|
gptkbp:dosage_form
|
solution for injection
|
|
gptkbp:duration
|
every 12 weeks
|
|
gptkbp:effective_date
|
gptkb:2018
FDA approved
|
|
gptkbp:financial_performance
|
stable for 24 months
|
|
gptkbp:formulation
|
sterile solution
|
|
https://www.w3.org/2000/01/rdf-schema#label
|
tildrakizumab
|
|
gptkbp:indication
|
moderate to severe plaque psoriasis
|
|
gptkbp:ingredients
|
gptkb:tildrakizumab
C6420 H9920 N1716 O1980 S44
|
|
gptkbp:invention
|
2028
patented
|
|
gptkbp:is_used_for
|
treatment of psoriasis
|
|
gptkbp:is_vulnerable_to
|
low
|
|
gptkbp:manager
|
subcutaneous
subcutaneous injection
|
|
gptkbp:marketed_as
|
gptkb:legislation
gptkb:Australia
gptkb:United_States
gptkb:Native_American_tribe
|
|
gptkbp:pharmacokinetics
|
long half-life
|
|
gptkbp:population
|
gptkb:Person
adults
|
|
gptkbp:provides_information_on
|
European Academy of Dermatology and Venereology
National Psoriasis Foundation
|
|
gptkbp:research_areas
|
gptkb:Company
dermatology
immunology
|
|
gptkbp:safety_features
|
generally well tolerated
|
|
gptkbp:side_effect
|
fatigue
headache
nausea
liver enzyme elevation
injection site reactions
thrombocytopenia
upper respiratory infections
serious infections
malignancies
|
|
gptkbp:storage
|
refrigerated
|
|
gptkbp:targets
|
gptkb:IL-23
|
|
gptkbp:traded_on
|
Ilumya
|
|
gptkbp:bfsParent
|
gptkb:ALX-0703
|
|
gptkbp:bfsLayer
|
5
|